Open an account

BioLine RX

BLRX · TEL

$2.21+$0.2345 (+11.84%)TodayMarket closed ·
Prev close $1.98

About BLRX

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The company is headquartered in Modiin, Central(Hamerkaz) and currently employs 24 full-time employees. The company went IPO on 2007-01-30. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Employees
24
Headquarters
Modiin, Central(HaMerkaz)
Listed
Jan 30, 2007
Sector
Health Care
Industry
Biotechnology
Website
biolinerx.com

BLRX key statistics

Market cap
32.86M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
17.99K
Volume
3.06K
Open price
$2.08
High today
$2.21
Low today
$2.07
52 Week high
$3.95
52 Week low
$1.95

BioLine RX (BLRX) at a glance

As of Oct 20, 2026, BioLine RX (BLRX) shares are priced at $2.21, giving the company a market cap of 32.86M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.07 and $2.21. The current price is 7.0% above the day's low and 0.0% below its high.

Volume so far is 3.06K shares, below the average of 17.99K shares a day.

Over the past year BioLine RX has ranged from $1.95 to $3.95, and now sits 13% of the way up that range.

BioLine RX met or beat analyst EPS estimates in 0 of the last 5 quarters. In Q2 FY26 it reported -$0.77 per share against an estimate of $0.00.

BLRX earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 5 quarters.

  1. Q3 FY15: reported -$0.12 per share against an estimate of -$0.0816
  2. Q3 FY23: reported -$0.30 per share against an estimate of $0.00
  3. Q1 FY24: reported -$0.01 per share against an estimate of $0.00
  4. Q3 FY24: reported -$0.07 per share against an estimate of $0.00
  5. Q2 FY26: reported -$0.77 per share against an estimate of $0.00

BLRX news

  • Press releasePRNewswire

    BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day

  • Press releasePRNewswire

    BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

  • Press releasePRNewswire

    BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update

  • Press releasePRNewswire

    BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

  • Press releasePRNewswire

    BioLineRx to Report Second Quarter 2026 Results on August 31, 2026

  • Press releasePRNewswire

    BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026

  • Press releasePRNewswire

    BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

  • Press releasePRNewswire

    BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

Similar companies

Companies in the same industry as BioLine RX

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.